AstraZeneca presented trial results for its IMFINZI cancer treatment at the European Society for Medical Oncology (ESMO) Congress in Madrid.
2 reports, 1 independent
Updated Sat 00:00
No new developments lately
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AstraZeneca presented trial results for its IMFINZI cancer treatment at the European Society for Medical Oncology (ESMO) Congress in Madrid.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
AstraZeneca
British-Swedish pharmaceutical company
- AstraZeneca presented trial results at the European Society for Medical Oncology (ESMO) Congress in Madrid, Spain.
- Geopolitical instability in the Middle East has led to significant corporate fallout, including the cancellation of Flutter's London Stock Exchange listing and AstraZeneca considering a move to the US market.
-
European Society for Medical Oncology
Professional organisation
Related events
- AbbVie presented clinical data at the European Society for Medical Oncology (ESMO) Congress held in Madrid.
- Hengrui Pharma and Guangdong Provincial People's Hospital presented research findings at the ESMO Congress on October 20, 2026.
- Researchers presented Phase 3 clinical data at the European Society for Medical Oncology (ESMO) Congress on September 21, 2026.
- Evaxion will present clinical trial data at the ESMO Congress 2025 in Berlin, utilizing therapy from Merck Sharp & Dohme.
- Study results were presented by Tempus and Pfizer at the ESMO Congress, focusing on ongoing collaboration regarding diagnostic barriers.